一名 CLL 患者在接受伊布替尼治疗期间出现自发性红斑。

IF 0.7 Q4 HEMATOLOGY

Case Reports in Hematology Pub Date : 2023-12-14 eCollection Date: 2023-01-01 DOI:10.1155/2023/1691996

Kim Abbegail Tan Aldecoa, Chef Stan L Macaraeg, Akash Dadlani, Sri Yadlapalli

{"title":"一名 CLL 患者在接受伊布替尼治疗期间出现自发性红斑。","authors":"Kim Abbegail Tan Aldecoa, Chef Stan L Macaraeg, Akash Dadlani, Sri Yadlapalli","doi":"10.1155/2023/1691996","DOIUrl":null,"url":null,"abstract":"Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-old patient with a known diagnosis of CLL on ibrutinib treatment.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10735723/pdf/","citationCount":"0","resultStr":"{\"title\":\"Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.\",\"authors\":\"Kim Abbegail Tan Aldecoa, Chef Stan L Macaraeg, Akash Dadlani, Sri Yadlapalli\",\"doi\":\"10.1155/2023/1691996\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-old patient with a known diagnosis of CLL on ibrutinib treatment.\",\"PeriodicalId\":46307,\"journal\":{\"name\":\"Case Reports in Hematology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-12-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10735723/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/1691996\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/1691996","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

伊布替尼是治疗慢性淋巴细胞白血病（CLL）的一线口服靶向药物。常见的不良反应有腹泻、疲劳和肌肉骨骼疼痛，但很少与视力障碍有关。在此，我们介绍了一例罕见的自发性红斑病例，患者 60 岁，已知诊断为 CLL，正在接受伊布替尼治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.

Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-old patient with a known diagnosis of CLL on ibrutinib treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Case Reports in Hematology HEMATOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks